Literature DB >> 30218781

Identification of nonalcoholic fatty liver disease following pancreatectomy for noninvasive intraductal papillary mucinous neoplasm.

Carrie Luu1, Ram Thapa2, Trevor Rose3, Katherine Woo1, Daniel Jeong3, Kerry Thomas3, Dung-Tsa Chen2, Mark Friedman1, Mokenge P Malafa1, Pamela J Hodul4.   

Abstract

BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) following pancreatectomy is a potential cause of long term morbidity in patients undergoing pancreatic resection with curative intent. Prior studies have reported an incidence of NAFLD up to 30% following pancreatectomy but the investigated cohorts were typically a mix of benign and malignant disease. Here we examined the incidence of NAFLD in a homogenous cohort of patients following pancreatectomy for benign intraductal papillary mucinous neoplasm (IPMN).
METHODS: A retrospective review of patients who underwent pancreatic resection for IPMN from 2000 to 2016 was performed. Post pancreatectomy CT/MRI scans were obtained as standard surveillance. We investigated changes in the liver parenchymal density on post surgical imaging to estimate the frequency with which NAFLD occurred. Radiographic criteria for NAFLD included Hounsfield units less than 40 on CT or liver:spleen ratio <0.9 on CT or MRI. Fischer's exact test, Kruskal-Wallis test, and logistic regression were performed.
RESULTS: Our study cohort included 109 patients who underwent pancreatectomy for nonmalignant intraductal papillary mucinous neoplasm with no evidence of NAFLD preoperatively and at least 6 months follow-up. Mean follow-up was 52 months (range 8-130/months). The incidence of postoperative NAFLD was 17/109 (15.6%). Most cases occurred within 12 months of pancreatectomy. On multivariate analysis, proximal pancreatectomy (pancreaticoduodenectomy) and development of atrophy of the pancreas remnant were significant risk factors for development of hepatic steatosis (p < 0.05).
CONCLUSION: Patients undergoing pancreatectomy for benign disease have a significant risk of developing NAFLD but the frequency is lower than previously reported in cohorts that included individuals with malignant disease. Highest risk was observed in individuals who underwent pancreaticoduodenectomy or developed pancreatic atrophy. Further investigations to define the mechanisms that promote steatosis and interventions to prevent subsequent morbidity from NAFLD are warranted.
Copyright © 2018 IJS Publishing Group Ltd. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hepatic steatosis; Intraductal papillary mucinous neoplasm; Pancreatectomy

Mesh:

Year:  2018        PMID: 30218781      PMCID: PMC7771269          DOI: 10.1016/j.ijsu.2018.09.002

Source DB:  PubMed          Journal:  Int J Surg        ISSN: 1743-9159            Impact factor:   6.071


  20 in total

Review 1.  AGA technical review on nonalcoholic fatty liver disease.

Authors:  Arun J Sanyal
Journal:  Gastroenterology       Date:  2002-11       Impact factor: 22.682

2.  Do pancrelipase delayed-release capsules have a protective role against nonalcoholic fatty liver disease after pancreatoduodenectomy in patients with pancreatic cancer? A randomized controlled trial.

Authors:  Sohei Satoi; Masayuki Sho; Hiroaki Yanagimoto; Tomohisa Yamamoto; Takahiro Akahori; Shoichi Kinoshita; Minako Nagai; Satoshi Hirooka; So Yamaki; Satoshi Nishiwada; Hironori Ryota; Naoya Ikeda; Yoshiyuki Nakajima; Masanori Kon
Journal:  J Hepatobiliary Pancreat Sci       Date:  2016-02-14       Impact factor: 7.027

3.  Effects of pancrelipase on nonalcoholic fatty liver disease after pancreaticoduodenectomy.

Authors:  Minako Nagai; Masayuki Sho; Sohei Satoi; Hideyoshi Toyokawa; Takahiro Akahori; Hiroaki Yanagimoto; Tomohisa Yamamoto; Satoshi Hirooka; So Yamaki; Shoichi Kinoshita; Satoshi Nishiwada; Naoya Ikeda; A-Hon Kwon; Yoshiyuki Nakajima
Journal:  J Hepatobiliary Pancreat Sci       Date:  2013-06-20       Impact factor: 7.027

4.  Randomized prospective trial of the effect of induced hypergastrinemia on the prevention of pancreatic atrophy after pancreatoduodenectomy in humans.

Authors:  Jin-Young Jang; Sun-Whe Kim; Joon-Koo Han; Sang-Jae Park; Youn-Chan Park; Young Joon Ahn; Yong-Hyun Park
Journal:  Ann Surg       Date:  2003-04       Impact factor: 12.969

Review 5.  Exocrine and endocrine pancreatic insufficiency after pancreatic surgery.

Authors:  Stefan Kahl; Peter Malfertheiner
Journal:  Best Pract Res Clin Gastroenterol       Date:  2004-10       Impact factor: 3.043

6.  Prevalence analysis of de novo hepatic steatosis following pylorus-preserving pancreaticoduodenectomy.

Authors:  Dae-Gwang Yoo; Bo-Hyun Jung; Shin Hwang; Song-Chul Kim; Ki-Hun Kim; Young-Joo Lee; Chul-Soo Ahn; Deok-Bog Moon; Kang-Mo Kim; Tae-Yong Ha; Sung-Hwa Kang; Nayoung Kim
Journal:  Dig Surg       Date:  2014-12-11       Impact factor: 2.588

7.  Insulin resistance in non-diabetic patients with non-alcoholic fatty liver disease: sites and mechanisms.

Authors:  E Bugianesi; A Gastaldelli; E Vanni; R Gambino; M Cassader; S Baldi; V Ponti; G Pagano; E Ferrannini; M Rizzetto
Journal:  Diabetologia       Date:  2005-03-04       Impact factor: 10.122

8.  Metabolic consequences of (regional) total pancreatectomy.

Authors:  C M Dresler; J G Fortner; K McDermott; D R Bajorunas
Journal:  Ann Surg       Date:  1991-08       Impact factor: 12.969

Review 9.  Development of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) after pancreaticoduodenectomy: proposal of a postoperative NAFLD scoring system.

Authors:  Hiroyuki Kato; Shuji Isaji; Yoshinori Azumi; Masashi Kishiwada; Takashi Hamada; Shugo Mizuno; Masanobu Usui; Hiroyuki Sakurai; Masami Tabata
Journal:  J Hepatobiliary Pancreat Sci       Date:  2009-10-07       Impact factor: 7.027

10.  The STROCSS statement: Strengthening the Reporting of Cohort Studies in Surgery.

Authors:  Riaz Ahmed Agha; Mimi R Borrelli; Martinique Vella-Baldacchino; Rachel Thavayogan; Dennis P Orgill
Journal:  Int J Surg       Date:  2017-09-07       Impact factor: 6.071

View more
  1 in total

Review 1.  Mechanisms of nonalcoholic fatty liver disease and implications for surgery.

Authors:  Ariel E Feldstein; Daniel Hartmann; Benedikt Kaufmann; Agustina Reca; Baocai Wang; Helmut Friess
Journal:  Langenbecks Arch Surg       Date:  2020-08-24       Impact factor: 3.445

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.